Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 22,059 | 24,600 | 15,468 | 19,993 | 23,640 |
| Other current assets | 203 | 341 | 740 | 412 | 1,226 |
| TOTAL | $22,262 | $24,941 | $16,208 | $20,405 | $24,866 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $22,262 | $24,941 | $16,208 | $20,405 | $24,866 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,418 | 4,038 | 3,778 | 5,741 | 3,754 |
| Accrued Expenses | 158 | 571 | 156 | 445 | 738 |
| TOTAL | $5,576 | $4,609 | $3,934 | $6,186 | $4,492 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $5,576 | $4,609 | $3,934 | $6,186 | $4,492 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,327 | 17,231 | 16,007 | 14,752 | 14,642 |
| Retained earnings | -47,623 | -41,742 | -36,034 | -31,985 | -25,289 |
| TOTAL | $16,686 | $20,332 | $12,274 | $14,219 | $20,374 |
| Total Liabilities And Equity | $22,262 | $24,941 | $16,208 | $20,405 | $24,866 |